Health Tech Daily Brief - September 24, 2026

Roche reported the drug sefaxersen achieved statistically significant and clinically meaningful results in a Phase 3 test in immunoglobulin A nephropathy, or IgAN. This antisense oligonucleotide, which came from Ionis Pharmaceuticals, could offer advantages over other drugs currently available for treating this rare chronic disease of the kidneys. The post Phase 3 Data Could Make Roche Drug a C…

medcitynews.com2026-09-23

Policy & Regulation

Electronic Prior Auth Standards Roll Out for Medicare Advantage, More

Texas Medical Association2026-09-23

CMS Proposes 16% Cut to Medicare Lab Test Rates

Medical Device and Diagnostic industry2026-09-23

FDA Medical Devices: Important Regulatory Considerations for Companies Seeking to Enter the U.S. Market

Foley & Lardner LLP2026-09-23

Funding & Deals

OpenEvidence’s Quiet Raise and Loud Pivot

Digital Health Wire2026-09-24

Oura Targets US$15 Billion Valuation in US IPO

Global Cosmetics News2026-09-24

Unilever Ventures Leads Series A Funding for Arey

Dealbreaker2026-09-23

Mental Health Tech

The danger of AI therapy

AUT2026-09-23

Pelago Unveils New Behavioral Health Platform for Substance Use, Mental Health and Behavioral Addiction Care

Pelago launched a behavioral health platform that integrates substance use, mental health and behavioral addiction care, using AI-powered triage to connect patients with appropriate treatment. The post Pelago Unveils New Behavioral Health Platform for Substance Use, Mental Health and Behavioral Addiction Care appeared first on MedCity News.

medcitynews.com2026-09-22